Adaptimmune Therapeutics plc Stock price
Equities
ADAP
US00653A1079
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.575 USD | -0.32% | +15.67% | +95.46% |
Financials (USD)
Sales 2024 * | 81.85M | Sales 2025 * | 73.92M | Capitalization | 390M |
---|---|---|---|---|---|
Net income 2024 * | -96M | Net income 2025 * | -120M | EV / Sales 2024 * | 4.76 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 5.28 x |
P/E ratio 2024 * |
-13.2
x | P/E ratio 2025 * |
-6.87
x | Employees | 449 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 15.06% |
Latest transcript on Adaptimmune Therapeutics plc
1 day | +3.95% | ||
1 week | +18.80% | ||
Current month | +0.64% | ||
1 month | -7.60% | ||
3 months | +119.75% | ||
6 months | +97.50% | ||
Current year | +99.24% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 57 | 07-12-31 | |
Adrian Rawcliffe
CEO | Chief Executive Officer | 52 | 15-02-28 |
Gavin Wood
DFI | Director of Finance/CFO | 54 | 20-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Kristen Hege
BRD | Director/Board Member | 60 | Oct. 31 |
Andrew Allen
BRD | Director/Board Member | 57 | 23-05-31 |
David Mott
CHM | Chairman | 58 | 14-08-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - | |
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 1.555 | -1.58% | 950 573 |
24-03-27 | 1.58 | +3.95% | 1,184,494 |
24-03-26 | 1.52 | +5.56% | 1,194,956 |
24-03-25 | 1.44 | 0.00% | 1,175,504 |
24-03-22 | 1.44 | +7.46% | 1,671,980 |
Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+99.24% | 390M | |
+2.56% | 108B | |
+10.02% | 104B | |
+7.57% | 23.66B | |
-11.91% | 22.1B | |
-3.29% | 19.71B | |
-35.98% | 18.2B | |
-14.02% | 16.19B | |
+4.61% | 13.72B | |
+35.05% | 12.22B |